Several other analysts have also recently commented on CUE. Zacks Investment Research cut Cue Biopharma from a buy rating to a hold rating in a report on Tuesday, October 8th. Robert W. Baird initiated coverage on Cue Biopharma in a report on Thursday, July 25th. They issued an outperform rating and a $13.00 target price on the stock.
CUE stock opened at $8.80 on Wednesday. The stock has a market cap of $201.89 million, a price-to-earnings ratio of -4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.17 and a quick ratio of 3.17. The company has a fifty day moving average price of $8.11 and a two-hundred day moving average price of $8.06. Cue Biopharma has a one year low of $4.16 and a one year high of $9.94.
About Cue Biopharma
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Further Reading: Why are gap-down stocks important?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.